Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCGK9H)

• Drug Name: VT-1129 Drug Info
• Synonyms: Metalloenzyme inhibitors (fungal infection); VT-1161; VT-1235; Metalloenzyme inhibitors (fungal infection), Viamet

Indication

Disease Entry	ICD 11	Status	REF
Onchocerciasis	1F6A	Phase 2	[1]
Onychomycosis	EE12.1	Phase 2	[2]
Cryptococcal meningitis infection	1D01.10	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 91886002
  CAS Number: CAS 1340593-70-5
  TTD Drug ID: DMCGK9H

Molecule-Related Drug Atlas

Drug(s) Targeting Enzyme unspecific (Enz)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[5]
Desoxyribonuclease	DMEZFXR	Female genital tract inflammation	GA0Z	Approved	[6]
HTI-101	DMURXMJ	Obesity	5B81	Phase 2	[7]
ASC-101	DMVNCSK	Haematological malignancy	2B33.Y	Phase 1/2	[8]
BXCL702	DMY9L4C	Haematological malignancy	2B33.Y	Phase 1	[9]
NZ-1002	DMINSRW	Lysosomal storage disease	5C56.Z	Terminated	[10]
A-11259	DMZ5NQP	Bacterial infection	1A00-1C4Z	Terminated	[11]
SRI-3072	DMBEUN6	Mycobacterium infection	1B10-1B21	Terminated	[12]
GW-278884	DMUG82P	Colorectal cancer	2B91.Z	Terminated	[13]
BM-13677	DMKITQN	Diabetic complication	5A2Y	Terminated	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Enzyme unspecific (Enz)	TT3C1VN	NOUNIPROTAC	Inhibitor	[4]
Lanosterol 14-alpha demethylase (CYP51A1)	TT67TDP	CP51A_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT01891305) A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7.
• [5] Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41.
• [6] Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52.
• [7] Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006.
• [8] ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Expression of a cytokinin synthesis gene from Agrobacterium tumefaciens T-DNA in basket willow (Salix viminalis). Physiologia Plantarum Volume 88, Issue 3, pages 439-445, July 1993.
• [11] The Identification of Nanomolar 1,4-benzoquinone Inhibitors of Shikimate Kinase. Aspergillus & Aspergillosis Website. 2002.
• [12] 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother. 2002 Jul;50(1):111-4.
• [13] WO patent application no. 2010,1112,71, Orally bioavailable lipid-based constructs.
• [14] Progress in medicinal chemistry, 1994. Page(448).